RhumbLine Advisers
PRME icon

RhumbLine Advisers’s Prime Medicine PRME Stock Holding History

RhumbLine Advisers’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$431K Buy
116,754
+2,485
+2% +$8.25K ﹤0.01% 2861
2026
Q1 		$398K Buy
114,269
+5,860
+5% +$22.3K ﹤0.01% 2748
2025
Q4 		$376K Sell
108,409
-1,378
-1% -$6.13K ﹤0.01% 2834
2025
Q3 		$608K Buy
109,787
+11,815
+12% +$48K ﹤0.01% 2562
2025
Q2 		$242K Buy
97,972
+16,072
+20% +$24.8K ﹤0.01% 3123
2025
Q1 		$163K Buy
81,900
+9,944
+14% +$25.4K ﹤0.01% 3207
2024
Q4 		$210K Buy
71,956
+1,909
+3% +$6.7K ﹤0.01% 3170
2024
Q3 		$271K Sell
70,047
-60
-0.1% -$278 ﹤0.01% 3077
2024
Q2 		$360K Buy
70,107
+17,595
+34% +$107K ﹤0.01% 2890
2024
Q1 		$368K Buy
52,512
+1,654
+3% +$12.5K ﹤0.01% 2852
2023
Q4 		$451K Sell
50,858
-101
-0.2% -$778 ﹤0.01% 2725
2023
Q3 		$486K Buy
50,959
+3,896
+8% +$50.6K ﹤0.01% 2628
2023
Q2 		$689K Buy
+47,063
New +$657K ﹤0.01% 2496

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

RhumbLine Advisers's PRME Position: Q2 2026 in Review

RhumbLine Advisers increased its Prime Medicine (PRME) stake by 2.2% in Q2 2026, buying an estimated $8.25K and bringing the position to 116,754 shares worth $431K. The position accounts for ﹤0.01% of the portfolio, ranked #2861.

RhumbLine Advisers first reported a position in PRME in Q2 2023 and has held it in 13 quarters since. The position peaked at $689K in Q2 2023. 187 funds tracked by Wall St. Rank hold PRME as of Q2 2026.

  • RhumbLine Advisers held 116,754 shares of Prime Medicine worth $431K as of Q2 2026.
  • RhumbLine Advisers bought 2,485 Prime Medicine shares in Q2 2026, an estimated $8.25K.
  • Prime Medicine made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #2861 holding.
  • RhumbLine Advisers first reported a position in Prime Medicine in Q2 2023 and has held it in 13 quarters since.
  • RhumbLine Advisers's Prime Medicine position peaked at $689K in Q2 2023.
  • 187 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.